Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558024 | 1.00 | NPC1 (0.30) | NPC1RAB9A | |
| SCHEMBL1558179 | 0.75 | — | — | |
| SCHEMBL1558178 | 0.75 | — | — | |
| SCHEMBL29245767 | 0.73 | KIF11 (0.32) | — | |
| SCHEMBL29245848 | 0.72 | — | — | |
| SCHEMBL31485604 | 0.72 | KDM1A (0.30) | — | |
| SCHEMBL11920697 | 0.71 | NPC1 (0.38) | NPC1RAB9A | |
| SCHEMBL7992156 | 0.71 | NPC1 (0.35) | NPC1RAB9A | |
| SCHEMBL25386740 | 0.71 | — | — | |
| SCHEMBL5669726 | 0.71 | SLC6A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2303846-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009156100-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | ROCK1, MYLK, ROCK2 | NPC1 2691/4885RAB9A 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.